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Tuberculosis (TB) and leprosy still represent significant public health challenges, espe-
cially in low- and lower middle-income countries. Both poverty-related mycobacterial 
diseases require better tools to improve disease control. For leprosy, there has been an 
increased emphasis on developing tools for improved detection of infection and early 
diagnosis of disease. For TB, there has been a similar emphasis on such diagnostic 
tests, while increased research efforts have also focused on the development of new 
vaccines. Bacille Calmette–Guérin (BCG), the only available TB vaccine, provides 
insufficient and inconsistent protection to pulmonary TB in adults. The impact of BCG 
on leprosy, however, is significant, and the introduction of new TB vaccines that might 
replace BCG could, therefore, have serious impact also on leprosy. Given the similarities 
in antigenic makeup between the pathogens Mycobacterium tuberculosis (Mtb) and 
M. leprae, it is well possible, however, that new TB vaccines could cross-protect against 
leprosy. New TB subunit vaccines currently evaluated in human phase I and II studies 
indeed often contain antigens with homologs in M. leprae. In this review, we discuss 
pre-clinical studies and clinical trials of subunit or whole mycobacterial vaccines for TB 
and leprosy and reflect on the development of vaccines that could provide protection 
against both diseases. Furthermore, we provide the first preclinical evidence of such 
cross-protection by Mtb antigen 85B (Ag85B)-early secretory antigenic target (ESAT6) 
fusion recombinant proteins in in vivo mouse models of Mtb and M. leprae infection. 
We propose that preclinical integration and harmonization of TB and leprosy research 
should be considered and included in global strategies with respect to cross-protective 
vaccine research and development.
Keywords: antigen 85B, early secretory antigenic target, Mycobacterium leprae, Mycobacterium tuberculosis, 
tuberculosis, leprosy, hybrid recombinant protein, vaccines
INTRODUCTION
Tuberculosis (TB) and leprosy are major infectious diseases that are caused by highly related 
mycobacterial pathogens, Mycobacterium tuberculosis (Mtb) and M. leprae. Although derived 
from the same mycobacterial ancestor (1), the target organs affected by these highly related myco-
bacteria (skin and nerves in leprosy; lungs and extrapulmonary lesions in TB) and the resulting 
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clinical symptoms, are strikingly different. Notwithstanding 
these differences, the two poverty-associated diseases also share 
important characteristics (2–4), including the important role of 
host cellular immunity in protection. In addition, both diseases 
display a wide spectrum of (immuno)-pathological features 
with characteristic granulomatous lesions that often result in 
chronic disease and require prolonged treatment with multidrug 
antibiotic therapies (5).
Although rarely lethal, leprosy is enormously feared for 
causing lifelong handicaps and deformities resulting from irre-
versible nerve damage. Leprosy is notable for its continued trans-
mission, which results in a stable annual number of approximately 
200,000 new cases (6). Moreover, predictions from mathematical 
modeling indicate that millions linger undetected (7).
Tuberculosis is a major threat due to its high morbidity and 
mortality, causing an estimated 10.4 million new cases and 1.8 
million deaths in 2015 alone (8). This scenario is worsened by 
HIV co-infection as well as by the emergence of multi-, extensive-, 
and total-drug resistance (8). Though not as threatening as for 
TB, anti-microbial resistance also poses a risk for leprosy (9–13), 
which needs to be considered in post-exposure prophylactic 
(PEP) treatment strategies in leprosy endemic areas that aim to 
reduce transmission by administering a single dose of antibiotics 
to those at high risk of developing leprosy (14).
In order to combat both diseases, global strategies have been 
endorsed, promoting the implementation of new drugs to shorten 
lengthy chemotherapeutic regimens, including strategies to avoid 
occurrence of de novo antibiotic resistance (15). In addition, 
research is focusing on development of improved diagnostics 
for detection of infection and early stages of disease allowing 
prophylactic and timely treatment, respectively. In contrast to 
chemoprophylaxis, vaccines would be expected to give rise to 
active as well as long-term protection. Therefore, development 
of novel vaccines is an additional top priority to control TB 
and leprosy by preventing disease and transmission (6, 16, 17). 
To explore this further, we here review the current vaccine 
development pipelines for TB and leprosy focusing on shared 
features and antigenic components, as well as highlight potential 
differences and incompatibilities.
BACILLE CALMETTE–GUÉRIN (BCG),  
ONE VACCINE FITS ALL?
Mycobacterium bovis, BCG still is the only vaccine used against 
TB worldwide (18, 19). It is the first live-attenuated bacterial 
vaccine administered to newborns at or shortly after birth 
and has been applied in 172 countries (20, 21). In spite of its 
efficacy against severe TB in children, protection against TB in 
adolescents and adults is not sufficient to impact on disease and 
transmission. This urges for new, more efficient vaccines, and 
alternative strategies to replace or complement BCG (22–24).
Although being introduced and licensed for prevention of TB, 
BCG was soon recognized to protect partly also from leprosy 
(25–27). The efficacy of BCG vaccination against TB and leprosy 
has been evaluated in numerous clinical trials and observational 
studies. However, these studies also revealed inconsistent and 
sometimes even contradictory results. BCG’s protective effects 
varied from 2 to 83% and from 58 to 74% in preventing pul-
monary and extrapulmonary TB, respectively (28), while its 
efficacy against leprosy ranged from 26 to 41% in experimental 
studies to 61% in observational studies, with mild differences 
between the paucibacillary (62%) and multibacillary (76%) 
forms (25, 29–31). BCG vaccination does not seem to protect 
against the third most common mycobacterial disease, Buruli 
ulcer’s disease, although a definite conclusion requires further 
well-designed prospective studies (32). Apart from its effect on 
mycobacterial diseases, BCG vaccination has been reported to 
have significant impact on unrelated diseases, probably through 
training of the innate immune system to respond more favorably 
to outer assaults (33, 34).
The remarkable differences in efficacy in various trials for 
TB and leprosy have been ascribed to several factors, includ-
ing diversity in the genetic fingerprints of the mycobacterial 
pathogens in different geographic areas (35, 36), the various BCG 
strains used in the studies (37, 38), the immune, nutritional, and 
socioeconomic status of the vaccinees enrolled (39), the presence 
of helminths or viral coinfections (21, 40, 41), the background 
exposure to and induction of immunity by environmental myco-
bacteria, which might mask or block the effects of BCG (42), but 
the precise reasons for this remain largely unclear.
Our incomplete understanding of which components of 
the human immune system are responsible for either suc-
cessful or inefficacious protection following BCG vaccination 
impedes the rational design of more effective vaccines (43). 
For instance, the limited efficacy of BCG in preventing local 
pulmonary TB disease compared to its effects on disseminated 
forms of TB is well documented, but remains unexplained (19). 
One hypothesis attributes this finding to its inability to induce 
durable and effective immune cells that home to the lung (19). 
Therefore, new routes of BCG administration, such as aerosol 
or intranasal immunization, are tested to initiate mucosal 
immunity and promote homing of immune cells to the lung 
mucosa (44, 45).
Another shortcoming of BCG is that its protective effects 
against TB as well as leprosy wanes over time, dropping to 14% 
efficacy after 10–20 years (46), indicating a suboptimal induction 
of long-term immune memory responses as discussed above 
(47, 48). Thus, BCG revaccination has been attempted in several 
countries. As a first attempt, a large trial in Malawi showed that 
BCG revaccination had limited impact on TB, while reducing the 
risk of leprosy with 50% (25, 49). Similarly, a large randomized 
controlled TB trial in Brazil showed that a second dose of BCG 
in adolescents did not confer better protection than a single 
dose given at birth (50). In contrast, for leprosy (30, 31), BCG 
revaccination is officially recommended in Brazil, since the 1970s 
for household contacts of leprosy patients as a boost to routine 
neonatal BCG vaccination. More recently, an extensive BCG 
revaccination trial of household contacts of leprosy patients in 
Brazil showed that the protection conferred by a booster BCG 
vaccination was 56% and was independent of previous BCG vac-
cination (29).
Notwithstanding, this lack of BCG boosting effects in TB and 
its beneficial effects on leprosy, BCG vaccination can also have less 
FIGURE 1 | Leprosy and tuberculosis (TB) vaccine pipelines. Schematic representation of leprosy (upper segment) and TB (lower segment) candidate vaccines in 
clinical trials. Source: adapted from Ref. (59), TBVI/Aeras September 2017 and https://clinicaltrials.gov/. The primary endpoints are indicated for each trial with the 
exception of TB/FLU-04L for which primary outcome is yet not registered. POI, prevention of infection; POR, prevention of recurrence; POD, prevention of disease.
3
Coppola et al. Cross-Protective Vaccines for Leprosy and TB
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 308
favorable effects, such as increasing the numbers of paucibacillary 
leprosy cases within the first months after BCG immunization 
(51). This is thought to be due to excessive boosting of pre-existing 
M. leprae-specific T cells in those already frequently exposed to 
the bacterium (51, 52), or to hyperinflammatory innate immunity 
(53, 54). Both mechanisms could lead to pathogenic immunity, 
such as increased numbers of paucibacillary leprosy and leprosy 
reactions (55).
Based on the premise that BCG might overcome the phe-
notypic cellular immunological tolerance against M. leprae in 
multibacillary leprosy, BCG immunotherapy has been trialed 
in leprosy patients in Venezuela in the 1980s (56). These studies 
met with limited success, since complications of this therapy 
were the occasional occurrence of disseminated cutaneous BCG 
lesions and the induction of leprosy reactional episodes (57). 
In contrast, a small-sized clinical trial in India studied a combina-
tion of MDT and immunotherapy with BCG in newly diagnosed 
leprosy patients and found a significant reduction in duration 
of reactions, incidence of type 2 reactions as well as in time to 
achieve bacterial clearance (58).
In summary, BCG has significant protective efficacy against 
severe TB in children and against leprosy in adults, while BCG 
revaccination has added value in leprosy, but not in TB. Future 
changes in TB vaccination policies might, therefore, also affect 
leprosy control. To further analyze this issue, we review cur-
rent vaccine development pipelines and policies for TB and 
leprosy, focusing on shared target product profiles and antigenic 
composition.
TABLE 1 | Homology between tuberculosis (TB) vaccine components and Mycobacterium leprae proteins.
Mycobacterium tuberculosis 
proteins
Identity Homology M. leprae orthologs Vaccine candidate References
Rv number Gene name Amino acid  
(aa) overlaps
% aa overlaps %
Rv3804c Antigen 85A  
(Ag85A)




Rv1886c Ag85B 269/324 84% 288/324 89% ML2028 H56/IC31; H4/IC31;  
TB/FLU-04L; LepVax
(61)
Rv3875 Early secretory  
antigenic target
35/91 39% 61/91 68% ML0049 H56/IC31 (68)
Rv2660 Rv2660 H56/IC31 (68)
Rv0288 TB10.4 68/96 71% 82/96 86% ML2531 H4/IC31; LepVax (61, 69)
Rv1813c Rv1813c nssf nssf nssf nssf ID93/GLA-SE (70)
Rv2608 PPE42 65/156 42% 88/156 56% PPE familya ID93/GLA-SE (70)
Rv3619c EsxV 59/92 64% 74/92 80% ML1056 ID93/GLA-SE (70)
Rv3620c EsxW 55/95 58% 73/95 76% ML1055 ID93/GLA-SE (70)
Rv1196 PPE18 173/419 41% 228/419 54% ML1054b M72/AS01E (71)
Rv0125 PepA 250/358 70% 292/358 82% ML2659 M72/AS01E (71)
Rv1860 Apa 197/298 67% 218/298 74% ML2055 LepVax (61)
Rv0455c Rv0455c 101/152 67% 113/152 75% ML2380 LepVax (61)
aAccession number not known; nnsf, no significant similarity found.
bPseudogene.
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VACCINES IN CLINICAL TRIALS:  
AT THE CROSSROAD BETWEEN 
LEPROSY AND TB
Although BCG vaccination trials in leprosy were executed 
decades ago, the current leprosy clinical vaccine pipeline is three 
times smaller than that of TB (Figure 1). This situation is relatively 
recent considering that in 2001 there were four candidate leprosy 
vaccines (being) tested in clinical trials vs. none against TB.
Vaccine Candidates
The leprosy vaccine pipeline employs both live (26, 60) and 
killed (26, 56, 61–63) whole cell mycobacterial vaccines as well as 
adjuvanted recombinant protein vaccines, such as LepVax (64), 
which have the advantage over BCG and other replicating live 
vaccines that they can be used safely also in immunocompro-
mised individuals (65). LepVax comprises a hybrid recombinant 
protein, linking four M. leprae antigens: ML2531, ML2380, 
ML2055, and ML2028 (LEP-F1) (Table 1), formulated in a stable 
emulsion with a synthetic, TLR4 agonist (GLA-SE) as adjuvant 
which has recently finished pre-clinical testing (66). In line with 
the extent of the epidemic, the TB vaccine pipeline is much larger. 
This includes candidates using various delivery platforms, such as 
virally vectored vaccines (67–70), adjuvanted subunits vaccines 
(71–74), recombinant BCGs (75), genetically attenuated Mtbs, 
as well as heat killed whole mycobacterial cell-based vaccines 
(76–79) (Figure  1). Evidently, the TB subunit vaccine pipeline 
has focused on a limited number of candidate Mtb antigens, 
in particular: Ag85A, Ag85B, early secretory antigenic target 
(ESAT6), TB10.4, Rv1813, Rv2608, Rv3619–3620, Rv1196, and 
Rv0125 (Table 1).
Clinical Endpoints
Leprosy and TB vaccines have different target product profiles 
and clinical endpoints to be considered in efficacy trials, e.g., 
prevention of infection (POI), prevention of disease (POD), or 
prevention of recurrence (POR) (80). POD require extensive 
longitudinal studies due to the long incubation times (years) in 
TB and leprosy (years-decades), and the limited incidence rates in 
most populations studied. For these reasons, alternative clinical 
trial designs have been developed using alternative biologically 
relevant endpoints, such as prevention of recurrence (POR) in 
cured TB patients, which evaluate whether relapse rates can be 
reduced by post-therapy vaccination; or shortening of treatment 
trials, which evaluate whether treatment length can be reduced by 
complementary immunotherapy with TB vaccines during the last 
phase of TB treatment. For leprosy, vaccines could be positioned 
to help preventing nerve damage in patients, since this clinical 
endpoint has a much higher frequency in leprosy patients, requires 
a shorter follow-up period and is a highly relevant endpoint in 
leprosy. New clinical trial designs with alternative endpoints will 
be important to accelerate the clinical evaluation of new vaccines 
for TB and leprosy, and signals detected in such studies can be 
validated in larger studies against classical endpoints, such as 
POD and perhaps POI.
Clinical Trials
In most vaccination trials for leprosy, the protective effects of the 
tested new vaccine candidates were equivalent to that of BCG 
(81). Only in one study, vaccination with Indian Cancer Research 
Centre bacilli (an M. leprae-related cultivable mycobacterium) 
and BCG plus killed M. leprae showed a twofold increased pro-
tection against leprosy compared to BCG alone (26). However, 
- M lep A g 8 5 -E S A T 6 M lep 8 5B M lep E SA T 6
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0








- M tb A g8 5B -E S A T 6 M tb 8 5B M tb E SA T 6
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0














1 0 0 0














1 0 0 0









FIGURE 2 | IFN-γ secretion after Ag85-ESAT immunization. C57BL/6j and HLA-A2tg mice B6.Cg-Tg (117) were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA) and housed under specific pathogen-free conditions. Recombinant proteins were overexpressed in E. coli BL21 (DE3) and purified to remove  
any traces of endotoxin as described in Ref. (116, 118). For the production of the antigen 85B (Ag85B)-early secretory antigenic target (ESAT6), hybrid recombinant 
hybrid protein, the Ag85B and ESAT6 genes were fused together by PCR with a linker coding for the amino acids NVA. C57BL/6j mice [(A); 13–14 animals per 
group] and HLA-A2tg mice [(B); 5 animals per group] were immunized three times subcutaneously with Mycobacterium tuberculosis (Mtb) Ag85-ESAT or 
Mycobacterium leprae Ag85-ESAT recombinant protein (25 µg) adjuvanted with GLA-SE [glucopyranosyl lipid adjuvant-stable emulsion (23) kindly provided by 
Infectious Disease Research Institute; Seattle, WA, USA; TLR4 agonist; 20 µg]; or CpG (ODN1826 5′-TCC ATG ACG TTC CTG ACG TT -3′; InvivoGen, San Diego, 
CA, USA; TLR9 agonist; 50 µg) (119). Splenocytes were harvested 4 weeks after final injections and restimulated in vitro with Mtb or M. leprae Ag85-ESAT hybrid 
recombinant proteins or the single Ag85B and ESAT6 recombinant proteins (all 10 µg/ml). IFN-γ secretion was analyzed by ELISA after 5 days. All mice were 
analyzed separately. Data shown indicate the mean and SE value of five mice per group.
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M. indicus pranii (MIP) (also known as Mycobacterium w.) 
induced protective efficacy below that of BCG. Notwithstanding 
this result, MIP was evaluated also in a second, large-scale, 
double-blind trial with a 9-year follow-up (62). In this study, the 
protective efficacy of MIP in vaccinated household contacts after 
3 years was the highest ever reported against leprosy (68%) for a 
vaccine other than BCG. However, its protective effect dropped 
considerably after 6 (60%) and 9 (28%) years of follow-up. Despite 
these conflicting results, MIP is currently being evaluated both 
as prophylactic and therapeutic vaccine against leprosy in two 
high endemic districts in India (82) in combination with a single 
dose of rifampicin (SDR). This design is reminiscent of a previous 
randomized vaccine field trial in which BCG as well as SDR was 
provided to leprosy contacts (83).
For TB, several vaccines and vaccine approaches are being 
pursued, with no new TB vaccine approved, yet for use, since 
the introduction of BCG in 1921. The results from the recent 
MVA85A vaccine phase 2b efficacy trial, the first new TB vaccine 
tested in an efficacy trial, since BCG, showed no improved protec-
tion in BCG-vaccinated South African infants (84), despite being 
highly immunogenic in adults (85). Several trials are ongoing 
(Figure 1), with the first outcomes to become available in 2018.
Correlates of Protection
Vaccine immunogenicity studies for both leprosy and TB vac-
cine candidates have mostly focused on their ability to induce 
type-1 cell-mediated immunity, particularly CD4+ Th cells 
releasing type 1 helper (Th1) cytokines. Indeed, Th1 immunity 
is widely considered to be key in controlling mycobacterial 
infections (86). HIV-induced CD4+ T  cell deficiency, and 
genetic or acquired impairments in type 1 cytokine signaling 
(IL12-IFN-γ axis), all increase susceptibility to mycobacterial 
infection and progressive disease in humans and animal models 
(87–90). In leprosy, the presence of Th1 cytokines in lesions or 
in lepromin skin reactions has been related to better clinical 
prognosis and to localized rather than disseminating disease 
(91, 92). Furthermore, individuals that showed large local reac-
togenicity after intradermal BCG administration or lepromin 
injection are reported to have less risk for leprosy onset (93). 
Observation from a small Dutch cohort of BCG-vaccinated 
individuals showed that high skin inflammation responders 
had a larger amount of C-reactive protein in their sera than the 
low skin inflammation responders. In the same study, at 4, 8, 
and 12 weeks post-BCG vaccination, PBMCs of individuals with 
stronger local reactogenicity induced higher IFN-γ production 
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after in vitro PPD stimulation than the one from the group with 
less local reaction to BCG (94). This suggests that skin reacto-
genicity after BCG vaccination causing local inflammation and 
systemic Th1 responses probably indicate protective immunity 
to mycobacteria. The failure of MVA85A against TB despite its 
induction of CD4+ Th1 immunity, the observation that BCG-
specific CD4+ and CD8+ T-cell responses did not correlate 
with protection against TB disease in one study (95) together 
with the limited results achieved by current leprosy vaccines, 
clearly underline the need for a better understanding of the host 
mechanisms that are responsible for protection against both 
TB and leprosy. Several recent reports in animal models and 
humans have reported the involvement of other cell subsets in 
leprosy and TB (96, 97). Discovering these mechanisms may well 
prove to be a critical step for designing more effective vaccines.
Besides BCG, only MIP and killed M. vaccae have been 
clinically evaluated for both leprosy and TB, although in dif-
ferent trial designs and target populations. MIP has been tested 
for its putative therapeutic efficacy in tuberculous pericarditis 
(98) and as mentioned above for its protective efficacy against 
leprosy (26, 62). Killed M. vaccae has been assessed for its abil-
ity to prevent TB and leprosy disease in patients or contacts. 
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FIGURE 3 | Quantification of serum antibodies. Following immunization of C57BL/6j (A) and HLA-A2 tg (B) mice with adjuvant alone, Mycobacterium tuberculosis 
(Mtb) Ag85-ESAT or Mycobacterium leprae Ag85-ESAT recombinant protein in GLA-SE (A) or CpG (B), antibody titers (OD450) against Mtb Ag85-ESAT, M. leprae 
Ag85-ESAT, or Mtb/M. leprae Antigen 85B (Ag85B) and early secretory antigenic target (ESAT6) were determined by ELISA as described in Ref. (120). As a control 
coating with BSA (0.4% in PBS) was used. Sera from immunized mice were collected from cardiac blood 3 weeks after final immunization Serum dilutions are 
shown on the x-axis. Test groups included 3–5 mice. All mice were analyzed separately. Results are shown for one representative animal.
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FIGURE 4 | Determination of bacterial burden. C57BL/6j mice were injected with 104 live Mycobacterium leprae (121) (viability: 11,000; in 40 µl PBS) in each hind 
foot pads 4 weeks after the final protein immunization. 7 months after M. leprae challenge, mouse footpads were harvested, and M. leprae were enumerated by 
RLEP PCR (122). HLA-A2tg mice were infected with live Mycobacterium tuberculosis (Mtb) strain H37Rv 6 weeks after the final protein immunization and 10 weeks 
after Bacille Calmette–Guérin (BCG) immunization (119). All animals included in the experiments were observed daily in order to ensure ethics requirements and to 
monitor any adverse effects possibly related to the vaccination or infection. (A) Bacteria were determined by the RLEP PCR from footpads from M. leprae infected 
C57BL/6j mice that had been immunized with GLA-SE adjuvant alone (−), M. leprae Ag85-ESAT/GLA-SE, Mtb Ag85-ESAT/GLA-SE, or heat killed M. leprae (HKML; 
2 × 108 in 40 µl; viability: 6,400) as indicated on the x-axis. Each symbol represents one mouse. Calculated bacterial loads are expressed as RLEP counts on the 
y-axis. Horizontal lines indicate median values with interquartile range. (B) CFUs were determined in lung homogenates from Mtb-infected unimmunized (−) or 
Mtb-infected HLA-A2 tg mice that were immunized with BCG1331 (106 CFU), M. leprae Ag85-ESAT or Mtb Ag85-ESAT as indicated under the x-axis. Each symbol 
represents one mouse. Bacterial loads are expressed as log10 bacterial counts. Horizontal lines indicate median values with interquartile range. CFU of test and 
control groups were compared to the controls using the Mann–Whitney test and a p < 0.01 was considered significant. * marks differences that remained significant 
after multiple test correction using Kruskal–Wallis testing with Dunn’s post-test.
However, the administration routes (intramuscular vs. oral vs. 
intradermal injection of M. vaccae) and the eligibility criteria for 
the recruitment in the two trials (inclusion or not of individuals 
with BCG scar; HIV-positivity; anti-mycobacterial therapy) 
were quite diverse, impeding direct comparison of the impact 
of M. vaccae vaccination on both diseases (63, 78).
ONE SUBUNIT VACCINE FOR BOTH  
TB AND LEPROSY?
With the exception of M. habana (60, 99), the majority of vac-
cines evaluated for both leprosy and TB were initially designed 
as TB vaccines, and only evaluated at a later stage for their 
potential in leprosy. Since M. leprae has undergone massive 
gene reduction (100), not all Mtb antigens that are potential 
targets for TB vaccines have corresponding homologs in 
M. leprae. The first examples are ID83/GLA-SE and ID93/
GLA-SE, two recombinant fusion proteins, formulated with the 
TLR4L-containing adjuvant GLA-SE, and consisting of three 
Mtb proteins: Rv1813, Rv2608, and Rv3620, with the further 
addition of Rv3619 in ID93. The amino acid (aa) sequences 
of Rv3619 and Rv3620 are 58 and 64% identical to the respec-
tive M. leprae proteins (ML1056 and ML1055, respectively) 
(Table  1). Likely due to these similarities, both Mtb hybrid 
recombinant proteins were also recognized by blood from 
paucibacillary leprosy patients, although latent Mtb infection 
could have explained these findings as well. Furthermore, when 
injected subcutaneously these vaccines reduced M. leprae-
induced inflammation and bacterial growth in mouse models 
of leprosy (65), suggesting that TB subunit vaccines might have 
efficacy also against leprosy.
In a similar approach, we have investigated another TB 
subunit vaccine candidate, consisting of two major secreted Mtb 
proteins: Mtb ESAT6 and Mtb Ag85B, both present in short-
term Mtb culture filtrates (101, 102). Ag85B is highly conserved 
among mycobacterial species, probably due to its critical role 
in cell wall synthesis as a mycolyltransferase (103). ESAT6 is a 
secreted virulence protein mainly restricted to the Mtb complex 
organisms (104). Both antigens have been extensively studied 
in the TB field over the past three decades and proved to be 
strongly recognized by CD4 Th1-cells of TB patients and latently 
TB infected (LTBI) individuals (105). Demonstrated to be 
immunodominant during Mtb infection, the two recombinant 
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proteins were fused into a recombinant hybrid protein, and 
adjuvanted with the Th1 inducing synthetic adjuvant IC31®. 
In several animal models, including mice, guinea pigs, and 
non-human primates, Ag85B-ESAT6/IC31 showed promising 
protective efficacy against TB disease (106, 107). Based on these 
results, the vaccine was progressed to human phase 1/2a trials 
(105, 108, 109). This work demonstrated the vaccine’s safety and 
its remarkable ability to induce long-lasting Th1-type immune 
reactivity in healthy or HIV-negative, mycobacterially naive 
individuals, LTBI, and BCG-vaccinated volunteers (109–111) 
even 3 years after the second vaccination.
In view of several characteristics, Ag85B-ESAT6 is an interest-
ing candidate for leprosy as well. Mtb ESAT6 and Ag85B share 
68 and 89% aa overlaps (homology according to pre-computed 
Tuberculist Blastp) with M. leprae homologs, ML0049, and 
ML2028, respectively (Table 1). These proteins are widely recog-
nized by antibodies of multibacillary leprosy patients (112, 113), 
as well as by IFN-γ secreting cells from paucibacillary leprosy 
patients (64). We previously demonstrated T-cell cross-reactivity 
between Mtb and M. leprae ESAT6 in leprosy and TB patients 
(114). Moreover, a previous study showed that Ag85B overex-
pression in BCG significantly increased BCG’s protective efficacy 
against M. leprae (115). To further explore and compare the effi-
cacy of Ag85B-ESAT6-based vaccines against TB and leprosy, we 
generated both Mtb Ag85B-ESAT6 and M. leprae Ag85B-ESAT6 
and studied their in vivo efficacy in mouse models of Mtb and 
M. leprae infection.
Mtb and M. leprae Ag85B-ESAT6-Based 
Vaccines: A Comparative Evaluation
In order to evaluate the immunogenicity of Mtb-Ag85B-
ESAT6 and M. leprae-Ag85B-ESAT6, both hybrid recombinant 
proteins were produced (116) and injected subcutaneously in 
wild-type C57BL/6j (BL/6) mice, as well as in C57BL/6j (BL/6) 
mice expressing an HLA-A*0201 transgene. The proteins 
were formulated with GLA-SE (TLR4 agonist) or CpG (TLR9 
agonist), respectively, both of which have been reported to 
drive Th1-type responses. As expected, we detected high 
levels of IFN-γ released by splenocytes from immunized mice 
in response to Mtb Ag85B-ESAT6, M. leprae Ag85B-ESAT6, 
and their individual components (Figure  2). Total IgG, IgA, 
and IgM levels against Mtb Ag85B-ESAT6, M. leprae Ag85B-
ESAT6, and the individual proteins were increased as well 
in both mouse strains following immunizations (Figure  3). 
Interestingly, the highest antibody titers were observed against 
Mtb Ag85B-ESAT6, regardless of whether Mtb Ag85B-ESAT6 
or M. leprae Ag85B-ESAT6 had been used to immunize BL/6 
mice (Figure 3A). Most importantly, both Mtb Ag85B-ESAT6/
GLA-SE or M. leprae Ag85B-ESAT6/GLA-SE vaccines were 
capable of inducing host control of Mtb and M. leprae infec-
tion to a significant and comparable extent. Interestingly, Mtb 
Ag85B-ESAT6/GLA-SE controlled M. leprae infection signifi-
cantly better than M. leprae Ag85B-ESAT6/GLA-SE (Figure 4). 
In summary, these results suggest that novel subunit vaccines 
designed for TB, such as Mtb Ag85B-ESAT6 could have efficacy 
against both TB and leprosy.
CONCLUDING REMARKS
Leprosy and TB are still major poverty-related health concerns. 
Leprosy is primarily endemic in geographic areas, where TB is 
also highly prevalent (115). To date, BCG has been used pre-
dominantly as a vaccine against TB, but it also contributes to the 
control of leprosy. However, due to its limited efficacy especially 
against pulmonary TB in adults, the main and contagious form 
of TB, novel vaccines are being developed to replace or boost 
BCG (Figure 1). Although these vaccines will likely also impact 
leprosy incidence, this issue is rarely considered, let alone studied 
in extensive trials.
There are two leprosy vaccine candidates, MIP in India (82) 
and LepVax (66), and the TB vaccine pipeline is much more 
advanced and diverse than the one for leprosy. Even though it 
is likely that a TB vaccine candidate will emerge, for none of the 
current TB candidate vaccines, the impact on leprosy is currently 
being taken into account.
Only two highly similar recombinant subunit TB vaccines, 
based on the same backbone design, have been tested for their 
potential use against leprosy (65). Here, we describe original 
data showing a second TB subunit candidate vaccine platform, 
based on Ag85B/ESAT6. Collectively, our data suggest that 
novel TB vaccine candidates can cross-protect against leprosy, 
providing support for integrating leprosy vaccine research 
with TB vaccine research (65, 81, 115). At the moment, the 
most advanced new TB vaccine candidates have been tested in 
India, Tanzania, China, South Africa, the first two of which 
have elevated incidences of leprosy. Thus far, none of these 
recent trials have included evaluation of impact on leprosy, 
unlike what was done decades ago for BCG(61). We contend 
that preclinical integration and harmonization of TB/leprosy 
discovery and development research would well be feasible 
with respect to the design of subunit vaccines, as we have in 
fact applied in our recent approach for vaccine antigen discov-
ery (123). With respect to antigen selection algorithms, it is of 
interest to consider the extensive genomic reduction that M. 
leprae has undergone during evolution (100, 124), causing this 
Mycobacterium to become a highly specialized and obligate 
intracellular pathogen (125). Studying M. leprae’s successful 
minimalistic approach will reveal genetic and metabolic path-
ways that pathogenic mycobacteria need to survive in the host, 
and inspire drug and vaccine efforts to combat both diseases 
which have put such a heavy toll on humans for millennia.
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